Phreesia, Inc. (NYSE:PHR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Phreesia, Inc. (NYSE:PHR) has been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $29.42.

A number of equities research analysts have issued reports on PHR shares. DA Davidson reaffirmed a “buy” rating and set a $32.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Truist Financial boosted their price target on shares of Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, September 6th. KeyCorp lowered their price target on shares of Phreesia from $27.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Canaccord Genuity Group reissued a “buy” rating and issued a $34.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 target price on shares of Phreesia in a research note on Friday, September 27th.

Phreesia Stock Performance

Shares of PHR opened at $18.47 on Friday. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -10.26 and a beta of 0.93. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03. The business’s fifty day simple moving average is $22.19 and its two-hundred day simple moving average is $22.11. Phreesia has a 12 month low of $14.17 and a 12 month high of $29.16.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.06. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The business had revenue of $102.12 million for the quarter, compared to the consensus estimate of $101.76 million. Research analysts anticipate that Phreesia will post -1.23 earnings per share for the current fiscal year.

Insider Buying and Selling at Phreesia

In related news, General Counsel Allison C. Hoffman sold 14,110 shares of Phreesia stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.03, for a total transaction of $367,283.30. Following the completion of the transaction, the general counsel now directly owns 121,003 shares in the company, valued at approximately $3,149,708.09. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, General Counsel Allison C. Hoffman sold 14,110 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.03, for a total value of $367,283.30. Following the transaction, the general counsel now owns 121,003 shares in the company, valued at $3,149,708.09. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Chaim Indig sold 5,295 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total transaction of $123,108.75. Following the completion of the transaction, the chief executive officer now directly owns 1,223,736 shares in the company, valued at approximately $28,451,862. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,107 shares of company stock valued at $1,035,226. 5.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Phreesia

A number of hedge funds have recently modified their holdings of the business. Capital International Investors grew its holdings in shares of Phreesia by 221.1% in the first quarter. Capital International Investors now owns 2,593,063 shares of the company’s stock valued at $62,052,000 after purchasing an additional 1,785,463 shares in the last quarter. Champlain Investment Partners LLC purchased a new stake in shares of Phreesia in the 1st quarter valued at about $29,941,000. Blair William & Co. IL raised its position in Phreesia by 42.6% in the 1st quarter. Blair William & Co. IL now owns 752,700 shares of the company’s stock valued at $18,012,000 after purchasing an additional 224,950 shares during the last quarter. Vanguard Group Inc. increased its position in Phreesia by 4.4% in the 4th quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock valued at $107,148,000 after acquiring an additional 194,035 shares during the period. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Phreesia during the second quarter worth about $4,078,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.